J&J to acquire cancer drug developer Ambrx Biopharma for $2 billion
January 08, 2024 at 09:09 AM EST
The deal, which was announced on the first day of the annual JPMorgan Healthcare Conference, makes J&J the latest drugmaker to bet on ADCs.
